Johnson & Johnson’s DePuy Synthes has acquired Sentio, which makes nerve localization technology for spine surgery, for an undisclosed amount.
Nerve localization technologies help physicians avoid injuring nerves while performing spine procedures. Most systems use several needle electrodes in the patient’s limbs to locate motor neurons in the spine. They then generate signals that a neuromonitoring specialist interprets, guiding the surgeon.
However, neurologic complications persist in spite of these nerve localization systems, DePuy said in a statement. These complications, including pain or weakness in the hip or leg, result from the bruising or stretching of nerves near the surgical area. Temporary complications affect 9.4% of patients, while permanent complications are reported in 2.5% of patients, a study showed.
Enter Sentio, which uses adhesive sensors placed on the skin at relevant muscle groups and gives the surgeon feedback in real time. Sentio’s system does not require a specialist to set it up or to interpret signals.
“With Sentio’s nerve localization technology, DePuy Synthes will strengthen its spine portfolio in decompression procedures as well as lateral surgery, and build a platform for future innovation in minimally invasive surgery,” said Ciro Römer, DePuy Synthes chairman, in the statement. “The surgeon-driven approach will also help us reach more customers operating in an ambulatory surgery setting. This acquisition underscores our commitment to investing in differentiated technologies that help us reach more customers and patients around the world.”
Sentio initially focused on a narrow market in southeast Michigan, but DePuy plans to use its network to roll the system out globally.
By Amirah Al Idrus
Source: Fierce Biotech
Coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are urgently needed. Allie Nawrat explores the promise of larazotide, the drug in development currently leading the pack.
Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.
Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.
